Steris PLC
STE
209.68
+1.03
+0.49%
Steris PLC
US · STE
#909 by market cap
Listed 1970
209.68
+1.03
+0.49%
Live - 5344 symbols - heartbeat 76s ago
· 2026-10-08 08:05
Pre-market
211.28
+0.76%
After-hours
209.68
0.00%
- Market cap
- 20.44B
- P/E (TTM)i
- 25.63
- P/Bi
- 2.84
- EPSi
- 7.93
- Div yieldi
- 1.20%
- 52W posi
- 21%
Reader sentiment
Are you bullish or bearish on STE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.89, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.73% YoY
Margins
- Gross margin
- 44.25%
- Operating margin
- 18.63%
- Net margin
- 13.18%
Key ratios & quality
- Enterprise valuei
- 21.97B
- PEG ratioi
- 0.27
- Altman Z-Scorei
- 4.89
PEG uses trailing P/E against the 3-year net income growth rate (94.07%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.78B | 3.03B | 3.11B | 4.22B | 4.54B | 5.14B | 5.46B | 5.94B |
| Gross profit | 1.17B | 1.32B | 1.34B | 1.88B | 1.98B | 2.22B | 2.40B | 2.63B |
| Selling & admin expenses | 669.94M | 716.73M | 731.32M | 1.32B | 1.09B | 1.25B | 1.33B | 1.41B |
| Research & development | 63.04M | 65.55M | 66.33M | 86.66M | 98.48M | 103.70M | 107.60M | 112.90M |
| Operating profit | 442.01M | 537.72M | 545.45M | 477.86M | 791.59M | 862.20M | 960.90M | 1.11B |
| Pretax profit | 369.03M | 498.75M | 517.53M | 366.80M | 680.27M | 702.80M | 796.20M | 1.05B |
| Tax | 64.28M | 90.90M | 120.66M | 82.34M | 124.07M | 149.50M | 184.70M | 262.20M |
| Net profit | 304.75M | 407.86M | 396.87M | 242.87M | 105.81M | 380.10M | 616.10M | 785.10M |
| Basic EPS | 4 | 5 | 5 | 3 | 1 | 4 | 6 | 8 |
| Diluted EPS | 3.55 | 4.76 | 4.63 | 2.48 | 1.07 | 3.81 | 6.20 | 7.93 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.48B | 1.39B | 1.46B | 1.50B | 1.59B | 1.49B |
| Gross profit | 641.20M | 628.00M | 645.90M | 655.50M | 697.10M | 684.20M |
| Selling & admin expenses | 333.90M | 353.80M | 349.70M | 352.30M | 351.80M | 369.70M |
| Research & development | 27.60M | 26.40M | 28.20M | 29.50M | 28.80M | 28.60M |
| Operating profit | 279.70M | 247.80M | 268.00M | 273.70M | 316.50M | 285.90M |
| Pretax profit | 197.30M | 231.90M | 253.10M | 257.80M | 304.50M | 273.50M |
| Tax | 50.50M | 53.90M | 60.60M | 63.50M | 84.20M | 72.50M |
| Net profit | 146.10M | 178.00M | 192.50M | 194.30M | 220.30M | 201.00M |
| Basic EPS | 1 | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.48 | 1.79 | 1.94 | 1.96 | 2.24 | 2.04 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.05B | 1.22B | 1.21B | 1.88B | 2.01B | 2.87B | 2.00B | 2.39B |
| Cash & ST investments | 220.63M | 319.58M | 220.53M | 348.32M | 208.36M | 207.02M | 171.70M | 439.60M |
| Inventory | 208.24M | 263.54M | 315.07M | 575.00M | 604.41M | 674.54M | 581.30M | 631.80M |
| Total assets | 5.07B | 5.44B | 6.57B | 11.42B | 10.82B | 11.06B | 10.15B | 10.74B |
| Total current liabilities | 465.20M | 503.61M | 577.92M | 922.22M | 861.84M | 931.13M | 1.02B | 1.15B |
| Short-term debt | -- | 19.81M | 22.77M | 179.35M | 90.07M | 117.18M | 159.20M | 154.70M |
| Long-term debt | 1.18B | 1.15B | 1.65B | 2.95B | 3.02B | 3.12B | 1.92B | 1.81B |
| Total liabilities | 1,887,273,000.00 | 2,022,657,000.00 | 2,683,003,000.00 | 4,878,957,000.00 | 4,734,667,000.00 | 4,748,351,000.00 | 3,531,000,000.00 | 3,540,000,000.00 |
| Total equity | 3.19B | 3.42B | 3.89B | 6.54B | 6.09B | 6.32B | 6.62B | 7.20B |
| Retained earnings | 1.34B | 1.66B | 1.94B | 2.00B | 1.91B | 2.09B | 2.48B | 3.02B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.00B | 2.06B | 2.11B | 2.29B | 2.39B | 2.45B |
| Cash & ST investments | 171.70M | 279.70M | 319.20M | 423.70M | 439.60M | 482.30M |
| Inventory | 581.30M | 641.20M | 658.50M | 673.50M | 631.80M | 712.10M |
| Total assets | 10.15B | 10.41B | 10.41B | 10.59B | 10.74B | 10.74B |
| Total current liabilities | 1.02B | 926.60M | 888.90M | 922.30M | 1.15B | 1.28B |
| Short-term debt | 159.20M | 35.30M | 35.30M | 34.40M | 154.70M | 279.00M |
| Long-term debt | 1.92B | 1.90B | 1.90B | 1.90B | 1.81B | 1.65B |
| Total liabilities | 3,531,000,000.00 | 3,435,100,000.00 | 3,388,100,000.00 | 3,423,500,000.00 | 3,540,000,000.00 | 3,514,900,000.00 |
| Total equity | 6.62B | 6.97B | 7.02B | 7.17B | 7.20B | 7.22B |
| Retained earnings | 2.48B | 2.60B | 2.73B | 2.86B | 3.02B | 3.15B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 539.51M | 590.56M | 689.64M | 684.81M | 756.95M | 973.30M | 1.15B | 1.34B |
| Depreciation & amortization | 225.92M | 197.24M | 219.24M | 553.10M | 552.90M | 565.20M | 476.20M | 486.50M |
| Free cash flow | 349.79M | 376.04M | 450.38M | 397.25M | 394.98M | 613.00M | 778.00M | 972.40M |
| Dividends paid | -112.50M | -123.03M | -133.84M | -163.17M | -183.50M | -200.60M | -219.90M | -241.80M |
| Stock buybacks / issuance | -81.49M | -51.24M | -14.65M | -55.78M | -308.57M | -11.80M | -211.30M | -235.50M |
| Ending cash balance | 220.63M | 319.58M | 220.53M | 348.32M | 208.36M | 207.00M | 171.70M | 439.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 260.80M | 420.00M | 287.80M | 298.20M | 335.40M | 367.10M |
| Depreciation & amortization | 122.30M | 119.40M | 121.70M | 122.00M | 123.40M | 123.80M |
| Free cash flow | 189.90M | 326.40M | 201.30M | 199.50M | 245.20M | 279.60M |
| Dividends paid | -56.00M | -56.20M | -61.90M | -61.90M | -61.80M | -61.40M |
| Stock buybacks / issuance | -200.00K | -10.60M | -100.50M | -50.10M | -74.30M | -115.50M |
| Ending cash balance | 171.70M | 279.70M | 319.20M | 423.70M | 439.60M | 482.30M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.53 | 12.40 | 10.93 | 4.68 | 1.70 | 6.11 | 9.53 | 11.35 |
| ROA %i | 5.92 | 7.76 | 6.62 | 2.71 | 0.96 | 3.46 | 5.80 | 7.49 |
| ROIC %i | 7.63 | 9.69 | 8.13 | 3.98 | 1.89 | 5.08 | 7.29 | 9.08 |
| 5-year avg ROE %i | 8.24 | 8.16 | 9.26 | 9.44 | 7.84 | 7.16 | 6.58 | 6.67 |
| EBIT margin %i | 14.90 | 17.78 | 17.85 | 8.81 | 5.41 | 16.49 | 16.16 | 18.67 |
| FCF / sales %i | 12.57 | 12.41 | 14.49 | 8.66 | 7.97 | 11.93 | 14.25 | 16.38 |
| Current ratioi | 2.27 | 2.43 | 2.10 | 2.04 | 2.33 | 3.08 | 1.96 | 2.09 |
| Quick ratioi | 1.69 | 1.80 | 1.44 | 1.24 | 1.25 | 1.31 | 1.19 | 1.34 |
| Debt / assetsi | 23.32 | 23.61 | 27.42 | 28.71 | 30.02 | 30.58 | 21.71 | 19.44 |
| LT debt / equityi | 37.23 | 37.14 | 45.87 | 47.46 | 51.97 | 51.82 | 30.94 | 26.90 |
| Interest coveragei | 9.21 | 13.38 | 14.92 | 4.51 | 2.42 | 5.87 | 10.23 | 18.25 |
| Revenue CAGR (3Y) %i | 7.51 | 5.07 | 5.85 | 14.93 | 14.39 | 18.25 | 8.93 | 9.38 |
| Net income CAGR (3Y) %i | 39.97 | 54.77 | 10.96 | -7.05 | -35.97 | -1.63 | 36.09 | 94.07 |
| FCF CAGR (3Y) %i | 39.71 | 14.40 | 15.52 | 4.33 | 1.65 | 10.82 | 25.11 | 35.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 9.53 | 9.72 | 10.12 | 10.43 | 11.35 | 11.37 |
| ROA %i | 5.80 | 6.30 | 6.67 | 6.87 | 7.49 | 7.62 |
| ROIC %i | 7.29 | 7.78 | 8.10 | 8.33 | 9.08 | 9.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.16 | 16.60 | 17.15 | 17.21 | 18.67 | 19.04 |
| FCF / sales %i | 14.25 | 16.31 | 16.86 | 15.74 | 16.38 | 15.33 |
| Current ratioi | 1.96 | 2.22 | 2.37 | 2.48 | 2.09 | 1.91 |
| Quick ratioi | 1.19 | 1.32 | 1.42 | 1.53 | 1.34 | 1.17 |
| Debt / assetsi | 21.71 | 19.88 | 19.77 | 19.39 | 19.44 | 19.04 |
| LT debt / equityi | 30.94 | 29.23 | 28.87 | 28.22 | 26.90 | 24.50 |
| Interest coveragei | 10.23 | 12.89 | 14.63 | 15.98 | 18.25 | 18.97 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Healthcare is the largest reported line at 70.23% of revenue, across 3 reported segments.
- The next-largest line, Applied Sterilization Technologies (AST), is a distant second at 19.94% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Healthcare70.23%
Applied Sterilization Technologies (AST)19.94%
Life sciences9.83%
Quote time 2026-10-08 08:05:21 · For reference only, not investment advice and not tailored to your situation.